410 related articles for article (PubMed ID: 34664210)
1. Targeting fatty acid metabolism for fibrotic disorders.
Hwang S; Chung KW
Arch Pharm Res; 2021 Oct; 44(9-10):839-856. PubMed ID: 34664210
[TBL] [Abstract][Full Text] [Related]
2. Cardiac fibrosis.
Frangogiannis NG
Cardiovasc Res; 2021 May; 117(6):1450-1488. PubMed ID: 33135058
[TBL] [Abstract][Full Text] [Related]
3. Antifibrotic activities of pirfenidone in animal models.
Schaefer CJ; Ruhrmund DW; Pan L; Seiwert SD; Kossen K
Eur Respir Rev; 2011 Jun; 20(120):85-97. PubMed ID: 21632796
[TBL] [Abstract][Full Text] [Related]
4. Poricoic acid A activates AMPK to attenuate fibroblast activation and abnormal extracellular matrix remodelling in renal fibrosis.
Chen DQ; Wang YN; Vaziri ND; Chen L; Hu HH; Zhao YY
Phytomedicine; 2020 Jul; 72():153232. PubMed ID: 32460034
[TBL] [Abstract][Full Text] [Related]
5. Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity.
Cheng L; Ge M; Lan Z; Ma Z; Chi W; Kuang W; Sun K; Zhao X; Liu Y; Feng Y; Huang Y; Luo M; Li L; Zhang B; Hu X; Xu L; Liu X; Huo Y; Deng H; Yang J; Xi Q; Zhang Y; Siegenthaler JA; Chen L
Arch Toxicol; 2018 Jan; 92(1):469-485. PubMed ID: 28871336
[TBL] [Abstract][Full Text] [Related]
6. Modulation of Oxidative Phosphorylation with IM156 Attenuates Mitochondrial Metabolic Reprogramming and Inhibits Pulmonary Fibrosis.
Willette RN; Mangrolia P; Pondell SM; Lee CYW; Yoo S; Rudoltz MS; Cowen BR; Welsch DJ
J Pharmacol Exp Ther; 2021 Nov; 379(3):290-300. PubMed ID: 34593558
[TBL] [Abstract][Full Text] [Related]
7. Suppression of TGF-β pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro.
Stahnke T; Kowtharapu BS; Stachs O; Schmitz KP; Wurm J; Wree A; Guthoff RF; Hovakimyan M
PLoS One; 2017; 12(2):e0172592. PubMed ID: 28231275
[TBL] [Abstract][Full Text] [Related]
8. Specific Features of Fibrotic Lung Fibroblasts Highly Sensitive to Fibrotic Processes Mediated via TGF-β-ERK5 Interaction.
Kadoya K; Togo S; Tulafu M; Namba Y; Iwai M; Watanabe J; Okabe T; Jin J; Kodama Y; Kitamura H; Ogura T; Kitamura N; Ikeo K; Takeda T; Kondo N; Takahashi K
Cell Physiol Biochem; 2019; 52(4):822-837. PubMed ID: 30946557
[TBL] [Abstract][Full Text] [Related]
9. Tropomyosin 2.1 collaborates with fibronectin to promote TGF-β
Bradbury P; Nader CP; Cidem A; Rutting S; Sylvester D; He P; Rezcallah MC; O'Neill GM; Ammit AJ
Respir Res; 2021 Apr; 22(1):129. PubMed ID: 33910572
[TBL] [Abstract][Full Text] [Related]
10. Melatonin: the dawning of a treatment for fibrosis?
Hu W; Ma Z; Jiang S; Fan C; Deng C; Yan X; Di S; Lv J; Reiter RJ; Yang Y
J Pineal Res; 2016 Mar; 60(2):121-31. PubMed ID: 26680689
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of CCN family proteins in fibrosis.
Sun C; Zhang H; Liu X
J Cell Physiol; 2021 Jun; 236(6):4195-4206. PubMed ID: 33222181
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice.
Huang X; Wang W; Yuan H; Sun J; Li L; Wu X; Luo J; Gu Y
Tohoku J Exp Med; 2016 Aug; 239(4):251-61. PubMed ID: 27439438
[TBL] [Abstract][Full Text] [Related]
13. Into the matrix: targeting fibroblasts in pulmonary fibrosis.
Sivakumar P; Ntolios P; Jenkins G; Laurent G
Curr Opin Pulm Med; 2012 Sep; 18(5):462-9. PubMed ID: 22847104
[TBL] [Abstract][Full Text] [Related]
14. Halofuginone regulates keloid fibroblast fibrotic response to TGF-β induction.
Marty P; Chatelain B; Lihoreau T; Tissot M; Dirand Z; Humbert P; Senez C; Secomandi E; Isidoro C; Rolin G
Biomed Pharmacother; 2021 Mar; 135():111182. PubMed ID: 33433355
[TBL] [Abstract][Full Text] [Related]
15. Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction.
Schimmel K; Jung M; Foinquinos A; José GS; Beaumont J; Bock K; Grote-Levi L; Xiao K; Bär C; Pfanne A; Just A; Zimmer K; Ngoy S; López B; Ravassa S; Samolovac S; Janssen-Peters H; Remke J; Scherf K; Dangwal S; Piccoli MT; Kleemiss F; Kreutzer FP; Kenneweg F; Leonardy J; Hobuß L; Santer L; Do QT; Geffers R; Braesen JH; Schmitz J; Brandenberger C; Müller DN; Wilck N; Kaever V; Bähre H; Batkai S; Fiedler J; Alexander KM; Wertheim BM; Fisch S; Liao R; Diez J; González A; Thum T
Circulation; 2020 Mar; 141(9):751-767. PubMed ID: 31948273
[TBL] [Abstract][Full Text] [Related]
16. Activated Human Lung Fibroblasts Produce Extracellular Vesicles with Antifibrotic Prostaglandins.
Lacy SH; Woeller CF; Thatcher TH; Pollock SJ; Small EM; Sime PJ; Phipps RP
Am J Respir Cell Mol Biol; 2019 Mar; 60(3):269-278. PubMed ID: 30265126
[TBL] [Abstract][Full Text] [Related]
17. Anti-fibrotic effects of tannic acid through regulation of a sustained TGF-beta receptor signaling.
Reed EB; Ard S; La J; Park CY; Culligan L; Fredberg JJ; Smolyaninova LV; Orlov SN; Chen B; Guzy R; Mutlu GM; Dulin NO
Respir Res; 2019 Jul; 20(1):168. PubMed ID: 31358001
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast autophagy in fibrotic disorders.
Del Principe D; Lista P; Malorni W; Giammarioli AM
J Pathol; 2013 Jan; 229(2):208-20. PubMed ID: 23018629
[TBL] [Abstract][Full Text] [Related]
19. Renin angiotensin aldosterone system in pulmonary fibrosis: Pathogenesis to therapeutic possibilities.
Gupta D; Kumar A; Mandloi A; Shenoy V
Pharmacol Res; 2021 Dec; 174():105924. PubMed ID: 34607005
[TBL] [Abstract][Full Text] [Related]
20. Defining therapeutic targets for renal fibrosis: Exploiting the biology of pathogenesis.
Yan H; Xu J; Xu Z; Yang B; Luo P; He Q
Biomed Pharmacother; 2021 Nov; 143():112115. PubMed ID: 34488081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
